Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Lavedan

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Psychiatry Research|January 5, 2010
Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidoneAndrew Thompson, Christian Lavedan, Simona Volpi
Neuropharmacology|December 24, 2014
Tasimelteon: a selective and unique receptor binding profileChristian Lavedan, Mark Forsberg, Anthony J Gentile
Pharmacogenomics|February 29, 2008
Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trialChristian Lavedan, Simona Volpi, Mihael H Polymeropoulos, et al.
The Journal of Clinical Psychiatry|July 4, 2009
Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophreniaSimona Volpi, Steven G Potkin, Anil K Malhotra, et al.
Neuroscience Letters|April 18, 2002
A mutation in the human neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degenerationChristian Lavedan, Stephanie Buchholtz, Robert L Nussbaum, et al.
Schizophrenia Research|January 20, 2009
Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophreniaMihael H Polymeropoulos, Louis Licamele, Simona Volpi, et al.
Lancet (London, England)|October 16, 2015
Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trialsSteven W Lockley, Marlene A Dressman, Louis Licamele, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Psychiatry Research|January 5, 2010
Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidoneAndrew Thompson, Christian Lavedan, Simona Volpi
Neuropharmacology|December 24, 2014
Tasimelteon: a selective and unique receptor binding profileChristian Lavedan, Mark Forsberg, Anthony J Gentile
Pharmacogenomics|February 29, 2008
Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trialChristian Lavedan, Simona Volpi, Mihael H Polymeropoulos, et al.
The Journal of Clinical Psychiatry|July 4, 2009
Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophreniaSimona Volpi, Steven G Potkin, Anil K Malhotra, et al.
Neuroscience Letters|April 18, 2002
A mutation in the human neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degenerationChristian Lavedan, Stephanie Buchholtz, Robert L Nussbaum, et al.
Schizophrenia Research|January 20, 2009
Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophreniaMihael H Polymeropoulos, Louis Licamele, Simona Volpi, et al.
Lancet (London, England)|October 16, 2015
Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trialsSteven W Lockley, Marlene A Dressman, Louis Licamele, et al.
Pageof 1